PAID ADVERTISEMENT
Targeting Residual Inflammatory Risk: The Next Frontier for Atherosclerosis Treatment and Prevention
Faculty: Paul Ridker, MD, MPH, Harvard Medical School
Learning Objectives:
- Understanding the importance of treating inflammation in preventing CV events in addition to LDL
- Understand how lose dose colchicine fits into current treatment patterns
This event is not part of the official Scientific Sessions 2023 as planned by the AHA Committee on Scientific Sessions Program.
